Type 2 diabetes research studies are a primary focus at Meridien Research

 

Since 1980, the rate of diabetes in the United States has quadrupled. Over 90% of patients with diabetes have type 2 diabetes. With over five decades of clinical experience, Louis B. Chaykin, MD, has treated a wide range of patients with diabetes and authored many studies on the latest therapeutic medications.

The Epidemic

The growing number of people diagnosed with diabetes, especially type 2, has reached epidemic proportions. Unfortunately, the rates of diabetes directly correlate with the rising problem of obesity. And, diabetes is a worldwide epidemic, affecting people across physical and cultural borders. This has been in the mainstream media for several years, yet the number of diabetics continue to rise, which has public health officials very worried.

Type 2 diabetes is preventable. Years of research have shown how exercise and diet can improve or maintain proper pancreatic and kidney function. Not all of type 2 diabetes is linked to weight and activity levels. A small population of diabetics are genetically predisposed and develop the disease regardless of their healthy eating and exercise habits. Several gene mutations substantially increase the risk of type 2 diabetes.

There are certain demographics for people living in the United States that make them more at risk than others:

– Obesity and overweight.
– Stress.
– Inactivity.
– Family history of Diabetes Mellitus.
– Race, including African American, Latino, Asian, and Native American.
– Age 60 years and older.

According to the American Diabetes Association:

– Children of a parent with type 2 diabetes before age 50 have a 1 in 7 chance to get diabetes.
– If the parent has diabetes after the age of 50, then the chance is 1 in 13.
– If both parents have type 2 diabetes, the child’s risk is an alarming 1 in 2, or 50/50 chance.

Latest Research for Type 2 Diabetes

Diabetes research has made enormous progress in medications and implants. Development of insulin analogues, including long-acting and short-acting, provide an alternative to human insulin. These new types of insulin also have new delivery methods—alternatives to injections. Some alternative insulins can be taken orally or inhaled.

Along with the newer forms of insulin and delivery methods, patients with type 2 diabetes have, “Two new classes of drugs, SGLT-2’s and GLP-1’s,” explained Dr. Chaykin. “For the first time ever, we have two drugs that not only improve glucose, but significantly reduce mortality from cardiovascular disease and total mortality.”

“We were directly involved with the SGLT-2 and GLP-1 drug studies that demonstrated cardiovascular benefit. The SGLT-2 drug reduced total mortality by 32% and cardiovascular disease mortality by 38%. This was a study that involved over 7,000 participants around the world!”

“The GLP-1 injectable medication demonstrated a 22% reduction for patients dying from cardiovascular disease and 15% reduction in total mortality delaying the development of kidney problems.”

Researchers have a better understanding of the body’s development of type 2 diabetes. With every passing year, they are working on better ways to control and manage type 2 diabetes to fight the growing epidemic. And, through new drug therapies, clinicians can help patients manage their insulin levels and improve their quality of life.

If you or someone you know has type 2 diabetes and might be interested in volunteering for one of Meridien Research’s type 2 diabetes, please contact us today at 888-777-8839!